flâneur

Gaining Ground on Geographic Atrophy

reviewofoptometry.com · 4,044 words · saved by 1 readers

June's issue is our 13th annual retina report, which explores the latest in clinical research and innovation in the detection and management of retinal diseases. Check out the other featured articles here: New drugs continue to emerge at a steady rate for neovascular macular degeneration (nAMD). The past two years alone have seen a refillable port delivery system, a biosimilar anti-VEGF and a new therapeutic, Vabysmo (Genentech/Roche). Geographic atrophy (GA), on the other hand, has been plagued by failed treatments for a disease that has no proven therapeutic intervention. The unmet need is high. For eyecare providers, it is gut-wrenching to watch GA patients eventually succumb to severe loss of central acuity, while at the very least, we have treatment to offer to those who develop nAMD. But is there hope on the horizon? We will dive into the elusive disease of GA to break down the complex pathophysiology and provide insight on potentially promising treatments and updates in multimod

Focus on Retina June's issue is our 13th annual retina report, which explores the latest in clinical research and innovation in the detection and management of retinal diseases. Check out the other featured articles here: Staging of Diabetes and Diabetic Retinopathy Genetic Testing in Retina: Practical Applications Identifying Conversion to Wet AMD Ne w drugs continue to emerge at a steady rate for neovascular macular degeneration (nAMD). The past two years alone have seen a refillable port delivery system, a biosimilar anti-VEGF and a new therapeutic, Vabysmo (Genentech/Roche). Geographic atr

related reading